Prudential PLC Purchases 137,399 Shares of Bristol Myers Squibb Company $BMY

Prudential PLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 47.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 427,147 shares of the biopharmaceutical company’s stock after buying an additional 137,399 shares during the period. Prudential PLC’s holdings in Bristol Myers Squibb were worth $19,773,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Trifecta Capital Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth $25,000. REAP Financial Group LLC grew its stake in Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares during the last quarter. Accent Capital Management LLC acquired a new position in Bristol Myers Squibb during the 1st quarter valued at about $33,000. CBIZ Investment Advisory Services LLC raised its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in Bristol Myers Squibb in the first quarter worth about $36,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Down 2.7%

BMY stock opened at $45.78 on Thursday. The company has a market capitalization of $93.19 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The firm’s fifty day simple moving average is $45.31 and its 200-day simple moving average is $46.60. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same period in the previous year, the firm posted $1.80 earnings per share. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Scotiabank assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price objective for the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Four analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $54.42.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.